Investigation announced for Investors in NASDAQ: CPRX shares over possible Securities Laws Violations by Catalyst Pharmaceuticals, Inc.

An investigation was announced concerning potential securities laws violations by Catalyst Pharmaceuticals, Inc. in connection with certain financial statements.

Investors who purchased shares of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Catalyst Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Coral Gables, FL based Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases.

On October 30, 2019, Catalyst issued a press release announcing “top-line results from CMS-001, a Phase 3 study evaluating amifampridine phosphate for the symptomatic treatment of genetically confirmed Congenital Myasthenic Syndromes (CMS) in adults and children aged 2 years and above.” The press release advised investors that “[w]hile individual patient improvements were observed in some patient sub-groups, the trial did not meet its primary endpoint of subject global impression (SGI) or the secondary endpoint of muscle function measure (MFM) across all tested subtypes.”

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) closed on November 5, 2019, at $4.64 per share.

Those who purchased shares of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) have certain options and should contact the Shareholders Foundation.

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

This release was published on openPR.